Last updated on February 2018

Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

Brief description of study

This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6 months vs. Group 2: Placebo s.c. for 6 months. After 6 months both groups will run into the follow up period for another 12 months up to month 18. Patients developing arthritis will be treated according to local guidelines.

Clinical Study Identifier: NCT02778906

Contact Investigators or Research Sites near you

Start Over

Martin Fleck, Prof. Dr. med.

Klinikum Bad Abbach
Bad Abbach, Germany
  Connect »

Ramona Koenig, Dr. med.

Kerckhoff-Klinik Bad Nauheim
Bad Nauheim, Germany
  Connect »

Eugen Feist, Prof. Dr. med.

Charite Berlin
Berlin, Germany
  Connect »

Kirsten Karberg, Dr. med.

Praxis f r Rheumatologie und Innere Medizin
Berlin, Germany
  Connect »

Rieke Alten, Dr. med.

Schlosspark Klinik
Berlin, Germany
  Connect »

Martin Feuchtenberger, Dr. med.

Clinic Burghausen
Burghausen, Germany
  Connect »

Axel Hueber, Dr. med. Dr. ...

University Clinic Erlangen
Erlangen, Germany
  Connect »

Frank Behrens, Dr. med.

Centrum f r innovative Diagnostik und Therapie (Ciri) Rheumatologie/Immunologie
Frankfurt, Germany
  Connect »

Reinhard Voll, Prof. Dr. med.

Universit tsklinik Freiburg
Freiburg, Germany
  Connect »

Xenofon Baraliakos, Dr. med.

Rheumazentrum Ruhrgebiet
Herne, Germany
  Connect »

Johannes Strunk, Prof. Dr. med.

Krankenhaus Porz Am Rhein
Koeln, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.